The U.S. Food and Drug Administration approved an expanded indication for Merck’s GARDASIL 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
https://www.pharmalive.com/wp-content/uploads/2019/10/Gardasil.jpg20053000Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2020-06-12 18:40:062020-06-15 19:32:09FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers